New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Enabling a new era in minimally invasive obesity treatment across Europe
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Relmada expects to initiate its Phase 3 program in the first half of 2026
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Poviztra is a second brand of Wegovy
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Subscribe To Our Newsletter & Stay Updated
